Welcome to our dedicated page for Alector SEC filings (Ticker: ALEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alector, Inc. (NASDAQ: ALEC) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the U.S. Securities and Exchange Commission’s EDGAR system. Alector is a late-stage clinical biotechnology company focused on neurodegenerative diseases, and its filings offer detailed insight into clinical progress, financial performance, and corporate actions.
Investors can review Alector’s Form 8-K filings for material events such as quarterly financial results, restructuring plans, and leadership changes. For example, 8-K reports describe the announcement of second and third quarter financial results, the Phase 3 INFRONT-3 trial outcome for latozinemab (AL001) in FTD-GRN and the associated reduction in workforce, and the appointment of Neil Berkley as Chief Financial Officer while he continues as Chief Business Officer. These filings also outline estimated restructuring charges and separation arrangements for departing executives.
Beyond current reports, users can access periodic filings such as Forms 10-K and 10-Q (when available) to examine Alector’s collaboration revenue, research and development and general and administrative expenses, net loss, and cash, cash equivalents, and investment balances. For a company developing late-stage and preclinical programs in neurodegeneration, these documents are key to understanding funding runway, partnering structures, and portfolio priorities.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points in lengthy documents, helping readers quickly grasp the implications of complex disclosures. The platform also makes it easier to track insider transaction reports on Form 4 and other ownership-related filings, so users can monitor how executives and major holders interact with ALEC shares. Use this page to navigate Alector’s regulatory history, from clinical trial updates to financial and governance events, with AI tools that streamline document review.
Alector, Inc. reported insider transaction activity via Form 144 relating to Common Stock. The filing lists 37,261 shares sold by Neil Berkley on 12/03/2025. It also records 45,520 restricted stock units vesting on 02/27/2026 and shows 110,374,418 shares (labelled) with a date of 03/02/2026.
Alector, Inc. report of proposed resale and recent dispositions of common stock. The filing lists 132,804 shares tied to the vesting of restricted stock units dated 02/27/2026 that are identified under “Securities To Be Sold.” It also reports 104,347 shares sold on 12/03/2025 as securities sold during the past three months. The entries name a broker and show Nasdaq as the market.
Alector, Inc. reports a Form 144 notice for the vesting and planned sale of 12,376 shares of Common Stock associated with restricted stock units that vested on 02/27/2026.
The filing also lists three recent sell transactions by Grace Wong-Sarad: 8,056 shares on 12/03/2025 ($9,019.50), 4,753 shares on 12/05/2025 ($5,751.13), and 4,079 shares on 02/26/2026 ($10,197.50).
Alector, Inc. Principal Accounting Officer Grace Wong-Sarad sold 4,079 shares of common stock in an open-market transaction at a price of $2.50 per share. Following this sale, she directly owns 118,903 shares of Alector common stock.
The filing notes that this sale was effected under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on September 5, 2025, which is designed to systematically execute trades over time.
ALEC Form 144 filing reports planned and recent sales of Common restricted stock. The filing lists planned restricted-stock sales of 347 shares on 03/01/2025 and 3,732 shares on 06/01/2025. It also records sales by Grace Wong-Sarad of 4,753 shares on 12/05/2025 and 8,056 shares on 12/03/2025.
Alector, Inc. files its Annual Report describing a clinical-stage neurology pipeline focused on genetically validated therapies for Alzheimer’s, Parkinson’s and related neurodegenerative diseases. The company uses targeted mechanisms to remove pathogenic proteins, replace deficient proteins and restore cellular function.
The lead asset, nivisnebart, a progranulin-elevating antibody partnered with GSK, has completed enrollment in a 76‑week Phase 2 PROGRESS‑AD trial in early Alzheimer’s disease, with an interim futility analysis planned for the first half of 2026. Alector also highlights wholly owned preclinical programs, including AL137 (anti‑amyloid beta), AL050 (GCase enzyme replacement) and ABC‑enabled siRNA candidates for tau, alpha‑synuclein and NLRP3.
The report emphasizes the proprietary Alector Brain Carrier (ABC) platform for blood‑brain barrier delivery across antibodies, enzymes and siRNA, and outlines an ongoing strategic alliance with GSK, which provided $700 million in upfront payments and up to $1.5 billion in potential milestones with U.S. profit‑sharing on key programs.
Alector, Inc. reported fourth quarter and full year 2025 results and highlighted progress across its neurodegeneration pipeline and Alector Brain Carrier (ABC) platform. Collaboration revenue fell to $6.2 million in the quarter and $21.0 million for the year, down sharply from $54.2 million and $100.6 million in 2024, mainly due to completing prior collaboration milestones.
Research and development expenses declined to $123.1 million for 2025 from $185.9 million, and general and administrative expenses decreased to $54.0 million from $59.6 million, reflecting prior reductions in force. Despite lower spending, the 2025 net loss widened to $142.9 million, or $1.39 per share, compared with a $119.0 million loss, or $1.23 per share, in 2024.
The company ended 2025 with $256.0 million in cash, cash equivalents, and investments and expects this to fund operations at least through 2027, while advancing programs including AL137, AL050, AL064, and the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) with an interim futility analysis planned in the first half of 2026.
RTW Investments, LP and Roderick Wong, M.D. report that they no longer beneficially own any shares of Alector, Inc. common stock as of 12/31/2025. Both list 0 shares with 0.0% of the class, with no sole or shared voting or dispositive power.
The filing describes RTW Investments as investment adviser to certain funds that previously held Alector shares and notes that those funds have the right to receive dividends or sale proceeds. The reporting persons state the securities were held in the ordinary course of business and not to change or influence control of Alector.
Alector, Inc. insider ownership update: Arnon Rosenthal reports beneficial ownership of 8,213,925 shares of Alector common stock, representing 7.4% of the outstanding shares based on 109,151,472 shares outstanding as of October 31, 2025.
The holding includes 1,736,295 shares owned directly, 132,804 shares issuable from restricted stock units vesting within 60 days of December 31, 2025, and 2,414,451 shares issuable upon option exercises within the same period. He also has shared voting and dispositive power over 3,930,375 shares held through family trusts for which he serves as trustee.
The Vanguard Group filed an amended Schedule 13G reporting its beneficial ownership of 6,908,054 shares of Alector Inc. common stock, representing 6.32% of the class as of 12/31/2025. Vanguard reports shared voting power over 605,402 shares and shared dispositive power over 6,908,054 shares, with no sole voting or dispositive power.
Vanguard states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Alector. It also notes an internal realignment effective 01/12/2026, after which certain subsidiaries or business divisions are expected to report beneficial ownership separately.